GeoVax Initiates Research on Needle-Free GEO-MVA Vaccine Delivery

GeoVax Labs, Inc. has announced a new research program focused on evaluating the GEO-MVA vaccine's delivery through Vaxxas' high-density microarray patch (HD-MAP) technology. This study, conducted at the University of Queensland, aims to assess the vaccine's immunogenicity, delivery efficiency, and thermostability when administered via HD-MAPs in preclinical models. The HD-MAP platform promises a needle-free, skin-targeted approach that could significantly improve vaccine accessibility and effectiveness, especially in low- and middle-income countries.

The initiative represents a strategic move by GeoVax to expand the application of its MVA platform, potentially leading to vaccines that are more thermostable, require lower doses, and eliminate the need for needles. Such advancements could be crucial for routine immunization and rapid deployment during outbreaks. The HD-MAP technology offers several advantages, including the possibility of self-administration, increased patient acceptance, higher immunogenicity, and reduced reliance on cold chain storage.

Supported by GeoVax and led by researchers at the University of Queensland, this study could pave the way for developing a thermostable, needle-free GEO-MVA vaccine suitable for pandemic response, biodefense stockpiling, and global immunization programs. The success of this research could mark a significant milestone in making vaccines more accessible and easier to administer worldwide.